New experimental drug MDX2004 enters human trials for advanced cancers

NCT ID NCT07110584

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This study tests a new drug, MDX2004, in 235 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must be 18 or older and have at least one measurable tumor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Calvary Mater Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hadassah University Hospital-Ein Kerem

    RECRUITING

    Jerusalem, 9574409, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Liverpool Hospital

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Princess Alexandra Hospital

    RECRUITING

    Woolloongabba, Queensland, 4102, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rambam Health Care Campus

    RECRUITING

    Haifa, 3109601, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Tel Aviv Sourasky Medical Center

    RECRUITING

    Tel Aviv, 6423906, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.